• Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis.

Contraindicated in:

• None.

Use Cautiously in:

• Moderate or severe hepatic impairment
• Severe renal impairment or end-stage renal disease
• OB: Safety not established in pregnancy
• Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
• Pedi: Safety and effectiveness not established in children.

CV: heart block.

Derm: erythema.

EENT: blurred vision, dry eyes, vertigo, vitreous floaters.

GI: dyspepsia.

Metab: ↓ serum vitamin A concentrations.

MS: arthralgia, muscle spasms.

Resp: upper respiratory tract infections, dyspnea.

Misc: infusion reactions.

Drug-Drug:

• None reported.

• Solution for injection: 2 mg/mL;

• IV (Adults ≥100 kg): 30 mg every 3 wk.
• IV (Adults <100 kg): 0.3 mg/kg every 3 wk.

Onpattro

• Contains a double-stranded small interfering ribonucleic acid (siRNA) that causes degradation of mutant and wild-type transthyretin (TTR) mRNA. through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.

• Improvement in neuropathy.

Therapeutic Classification: n/a

Pharmacologic Classification:

Absorption: IV administration results in complete bioavailability.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Primarily metabolized by nucleases to nucleotides; <1% excreted in urine as unchanged drug.

Half-life: 3.2 days.

(serum TTR concentrations)

• Explain purpose of patisiran to patient.
• Advise patient to take supplement of vitamin A at recommended daily allowance and to notify health care professional if symptoms of vitamin A deficiency (night blindness) occur.
• Advise patient to notify health care professional immediately if signs and symptoms of infusion-related reactions occur.
• Rep: Advise patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding. Encourage pregnant patients to enroll in the pregnancy exposure registry that monitors pregnancy outcomes in women exposed to patisiran during pregnancy by calling 1-877-256-9526 or by contacting alnylampregnancyprogram@iqvia.com.

pat-i-SIR-an

NDC Code^*

• 71336- Alnylam Pharmaceuticals, Inc.
  • 71336-1000- Onpattro
    • 71336-1000-1- 1 VIAL, SINGLE-DOSE in 1 CARTON (71336-1000-1) > 5 mL in 1 VIAL, SINGLE-DOSE